Disease Pharma Companies Pharmaceutical Companies 
Drug Target Review
DECEMBER 20, 2024
Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. These digital twins allow pharmaceutical companies to design clinical trials with fewer participants, while still providing reliable evidence to assess a drugs effectiveness.
DrugBank
JUNE 27, 2024
They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 22, 2020
Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions.
The Connected Lab
APRIL 8, 2020
To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development?
The Open Targets Blog
OCTOBER 24, 2023
OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs. We primarily work on immune system diseases, integrating data and analyses from OTG on a large scale. However, the API presented two challenges. Why did you decide to share this openly?
Drug Target Review
MAY 23, 2023
Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. A changed composition of the gut microbiota is a characteristic trait of inflammatory bowel disease. More than 6.8
H1 Blog
JULY 30, 2024
Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.
Expert insights. Personalized for you.
128 
Let's personalize your content